Tim ireland | Xinhua News Agency | Getty Images
The company announced on Saturday that three phases of AstraZeneca’s Coronavirus vaccine had resumed in the UK earlier this week.
AstraZeneca said it received confirmation from the Medicine Health Regulatory Authority of the United Kingdom that it was safe to resume clinical trials. The company declined to disclose medical information about the trial stagnation, but indicated earlier this week that a possible unexplained illness was under investigation.
The company said that “the standard review process began a voluntary moratorium for all global tests on 6 September” so that independent committees and internal regulators could review safety data. Although tests may now resume in the UK, the status of tests elsewhere is unclear.
AstraZeneca said in a statement, “The company will continue to work with health authorities worldwide and may begin to provide the vaccine broadly, equally and with no benefit under other clinical trials . ”
The University of Oxford, which developed the vaccine in partnership with AstraZeneca, said on Saturday that some 18,000 people had received vaccinations in the study so far.
“In such large trials, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure a careful assessment of safety,” Oxford said in a statement.
STAT News reported earlier this week that AstraZeneca CEO Pascal Soriot said during a private conference call that a woman in the UK had “potentially unexplained illness”, a neurological disorder with a spinal inflammatory disorder. Used to exhibit symptoms known as transverse myelitis. STAT reported that investment bank JP Morgan made the call.
On the same call, Soriot also confirmed that AstraZeneca’s clinical trials had been stopped once before in July after an experienced neurological symptom, but the disease was found to be unrelated to the experimental vaccine.
Ostrazeneca’s potential coronavirus vaccine, which was developed in partnership with scientists at the University of Oxford, is at the forefront of a race toward a safe and effective vaccine that could be a bet in a global pandemic. The company launched its late-stage trial in late August. It is one of at least three vaccine candidates, along with Pfizer and Modern, in late-stage trials.
The US has invested more than $ 10 billion in six efforts to bring the coronavirus vaccine to market. On May 21, the US announced that the candidate would invest $ 1.2 billion in AstraZeneca’s effort in exchange for at least 300 million doses, if the candidate proves sufficiently safe and effective.